Stanislav Henkin

Dr. Stanislav Henkin

orcid

Research Focus & Metrics

Academic Career Length

12Years (2015-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 November 2021 in Cardiology Clinics
Verified
Journal Article
Closed access
ESEthan M. Senser
Ethan M. Senser
SMShantum Misra
Shantum Misra
SHStanislav Henkin
Stanislav Henkin

25 March 2024 in Journal of Thrombosis and Haemostasis
Verified
Journal Article
Closed access
RMRobert D. McBane
Robert D. McBane
CLCharles Lawrence Loprinzi
Charles Lawrence Loprinzi
TZTyler Zemla
Tyler Zemla
ATAlfonso Tafur
Alfonso Tafur
KSKristen Sanfilippo
Kristen Sanfilippo
WWWaldemar E. Wysokinski
Waldemar E. Wysokinski

10 February 2021 in Vascular Medicine
Verified
Journal Article
Open access
PDF file
ECEunjung Choi
Eunjung Choi
SHStanislav Henkin
Stanislav Henkin
Raynaud’s phenomenon, which is characterized by episodic digital pallor, cyanosis and rubor upon exposure to cold environment or to stress, is relatively common, although the prevalence depends on the climate. Still, it is under-diagnosed, under-treated, and often confused with other conditions. Primary Raynaud’s phenomenon (i.e., Raynaud disease) must be distinguished from secondary Raynaud’s phenomenon (i.e., Raynaud syndrome) as long-term morbidity and outcomes differ vastly between the two conditions. Additionally, the practitioner must differentiate between Raynaud’s phenomenon and related vascular disorders, such as acrocyanosis, pernio, and livedo reticularis. In this article, we review differences between the conditions and suggest an approach to diagnosis and treatment strategy for these disorders.

9 October 2022 in Vascular Medicine
Verified
Journal Article
Open access
CLChristopher Lee
Christopher Lee
JCJesse A Columbo
Jesse A Columbo
DSDavid H Stone
David H Stone
MCMark A Creager
Mark A Creager
SHStanislav Henkin
Stanislav Henkin
Patients undergoing major vascular surgery have an increased risk of perioperative major adverse cardiovascular events (MACE). Accordingly, in this population, it is of particular importance to appropriately risk stratify patients’ risk for these complications and optimize risk factors prior to surgical intervention. Comorbidities that portend a higher risk of perioperative MACE include coronary artery disease, heart failure, left-sided valvular heart disease, and significant arrhythmic burden. In this review, we provide a current approach to risk stratification prior to major vascular surgery and describe the strengths and weaknesses of different cardiac risk indices; discuss the role of noninvasive and invasive cardiac testing; and review perioperative pharmacotherapies.

1 October 2015 in Texas Heart Institute Journal
Verified
Journal Article
Closed access
SHStanislav Henkin
Stanislav Henkin
SNSara Negrotto
Sara Negrotto
PPPeter M. Pollak
Peter M. Pollak
MCMichael W. Cullen
Michael W. Cullen
DOD. Fearghas O'COchlain
D. Fearghas O'COchlain
RWR. Scott Wright
R. Scott Wright
Platypnea-orthodeoxia syndrome is an uncommon condition of positional dyspnea and hypoxemia; symptoms occur when the patient is upright and resolve with recumbency. Causes can be broadly categorized into 4 groups: intracardiac shunting, pulmonary shunting, ventilation-perfusion mismatch, or a combination of these. Platypnea-orthodeoxia syndrome should be suspected when normal arterial oxygen saturations are recorded while an individual is supine, followed by abrupt declines in those saturations when upright. Further investigations with use of imaging and cardiac catheterization aid in the evaluation. When platypnea-orthodeoxia syndrome is due to intracardiac shunting without pulmonary hypertension, intracardiac shunt closure can be curative. In this article, we report a case of platypnea-orthodeoxia syndrome in an 83-year-old woman who was successfully treated by means of percutaneous transcatheter closure of an atrial septal defect.

2 April 2024 in Journal of the American Heart Association
Verified
Journal Article
Open access
JSJennifer A. Sumner
Jennifer A. Sumner
EKEsther S. H. Kim
Esther S. H. Kim
MWMalissa J. Wood
Malissa J. Wood
GCGerald Chi
Gerald Chi
JNJessica Nolen
Jessica Nolen
SNSahar Naderi
Sahar Naderi
Background: Myocardial infarction secondary to spontaneous coronary artery dissection (SCAD) can be traumatic and potentially trigger posttraumatic stress disorder (PTSD). In a large, multicenter, registry‐based cohort, we documented prevalence of lifetime and past‐month SCAD‐induced PTSD, as well as related treatment seeking, and examined a range of health‐relevant correlates of SCAD‐induced PTSD.Methods and Results: Patients with SCAD were enrolled in the iSCAD (International SCAD) Registry. At baseline, site investigators completed medical report forms, and patients reported demographics, medical/SCAD history, psychosocial factors (including SCAD‐induced PTSD symptoms), health behaviors, and health status via online questionnaires. Of 1156 registry patients, 859 patients (93.9% women; mean age, 52.3 years) completed questionnaires querying SCAD‐induced PTSD. Nearly 35% (n=298) of patients met diagnostic criteria for probable SCAD‐induced PTSD in their lifetime, and 6.4% (n=55) met criteria for probable past‐month PTSD. Of 811 patients ever reporting any SCAD‐induced PTSD symptoms, 34.8% indicated seeking treatment for this distress. However, 46.0% of the 298 patients with lifetime probable SCAD‐induced PTSD diagnoses reported never receiving trauma‐related treatment. Younger age at first SCAD, fewer years since SCAD, being single, unemployed status, more lifetime trauma, and history of anxiety were associated with greater past‐month PTSD symptom severity in multivariable regression models. Greater past‐month SCAD‐induced PTSD symptoms were associated with greater past‐week sleep disturbance and worse past‐month disease‐specific health status when adjusting for various risk factors.Conclusions: Given the high prevalence of SCAD‐induced PTSD symptoms, efforts to support screening for these symptoms and connecting patients experiencing distress with empirically supported treatments are critical next steps.Registration: URL:https://www.clinicaltrials.gov; Unique identifier: NCT04496687.